William Kevin Kelly, DO | Authors

Articles

Selecting Therapy for Patients with CRPC

December 19, 2013

William Kevin Kelly, DO, professor of medical oncology and urology, Thomas Jefferson University, discusses the possibility of preselecting which castration-resistant prostate cancer (CRPC) patients will be sensitive to chemotherapy or hormone therapy.